Business Description
Medincell SA
ISIN : FR0004065605
Total Employee Number:
150Compare
Compare
Traded in other countries / regions
MEDCL.France0ACH.UKMEB.GermanyMDCLF.USA IPO Date
2018-10-08Description
Medincell SA is a clinical- and commercial-stage biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas, combining its proprietary BEPO technology with active ingredients already known and marketed. Its product portfolio includes UZEDY, mdc-TJK (Olanzapine LAI) and mdc-CWM (intra-articular celecoxib). The Company has a single operating segment: the conduct of research and development on biodegradable polymer-based processes for the controlled and prolonged delivery of active pharmaceutical ingredients into the human body and animals.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.48 | |||||
Equity-to-Asset | 0.03 | |||||
Debt-to-Equity | 18.74 | |||||
Debt-to-EBITDA | -2.39 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.94 | |||||
Beneish M-Score | -9.75 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 14 | |||||
3-Year EBITDA Growth Rate | 11.8 | |||||
3-Year EPS without NRI Growth Rate | 9.5 | |||||
3-Year FCF Growth Rate | 3.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 80.23 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 53.62 | |||||
9-Day RSI | 49.17 | |||||
14-Day RSI | 47.05 | |||||
3-1 Month Momentum % | -11.25 | |||||
6-1 Month Momentum % | 9.55 | |||||
12-1 Month Momentum % | 45.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.67 | |||||
Quick Ratio | 4.67 | |||||
Cash Ratio | 4.1 | |||||
Days Sales Outstanding | 24.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.4 | |||||
Shareholder Yield % | -4.94 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -106.44 | |||||
Net Margin % | -160.27 | |||||
EBITDA Margin % | -123.07 | |||||
FCF Margin % | -136.25 | |||||
OCF Margin % | -125.78 | |||||
ROA % | -34.37 | |||||
ROIC % | -65.6 | |||||
3-Year ROIIC % | -9.86 | |||||
ROC (Joel Greenblatt) % | -513.11 | |||||
ROCE % | -38.55 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 29.18 | |||||
PS Ratio | 42.01 | |||||
PB Ratio | 289.57 | |||||
EV-to-EBIT | -33.19 | |||||
EV-to-EBITDA | -35.72 | |||||
EV-to-Revenue | 43.96 | |||||
EV-to-Forward-Revenue | 31.18 | |||||
EV-to-FCF | -32.56 | |||||
Price-to-GF-Value | 0.93 | |||||
Earnings Yield (Greenblatt) % | -3.01 | |||||
FCF Yield % | -3.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Medincell SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 19.522 | ||
| EPS (TTM) (€) | -0.94 | ||
| Beta | 0.9377 | ||
| 3-Year Sharpe Ratio | 0.97 | ||
| 3-Year Sortino Ratio | 2.32 | ||
| Volatility % | 82.58 | ||
| 14-Day RSI | 47.05 | ||
| 14-Day ATR (€) | 0.87348 | ||
| 20-Day SMA (€) | 24.659 | ||
| 12-1 Month Momentum % | 45.73 | ||
| 52-Week Range (€) | 16.77 - 39.68 | ||
| Shares Outstanding (Mil) | 35.91 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Medincell SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Medincell SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Medincell SA Frequently Asked Questions
What is Medincell SA(XPAR:MEDCL)'s stock price today?
The current price of XPAR:MEDCL is €24.04. The 52 week high of XPAR:MEDCL is €39.68 and 52 week low is €16.77.
When is next earnings date of Medincell SA(XPAR:MEDCL)?
The next earnings date of Medincell SA(XPAR:MEDCL) is .
Does Medincell SA(XPAR:MEDCL) pay dividends? If so, how much?
Medincell SA(XPAR:MEDCL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Medincell SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers